CVC
CVC Limited
🇦🇺 ASX
💸 FINANCIALS
👑 Overview
📈 Performance
💰 Dividends
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-1.10%
Annual Growth
5 years average annual growth
💰
3.61%
Annual dividend yield
Based on the most recent dividend
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
CVC Ltd. engages in the provision of investment, development and venture capital, property finance and development, investment in listed entities, and funds management. The company is headquartered in Sydney, New South Wales. The firm's principal activities include property finance and development, the provision of investment and development capital and investment in other non-property opportunities. Its segments include property investment and non-property investment. The property investment segment includes investments in property related ordinary equity, preference equity, joint ventures, options to acquire an interest in direct property subject to planning outcomes and property backed lending. The non-property investment segment comprises listed investments, unlisted investments and secured lending opportunities that are non-property related. This segment also includes receivables, litigation claims and other investments. Its subsidiaries include Biggee Pty Limited, CVC Caboolture Unit Trust and Biomedical Systems Pty Limited.
📈 Performance
Price History
+55.25%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💰 Dividends
Payouts
💰 Annual Dividend Yield*
3.61%
💰 Annual Dividend Earnings Per $1,000 invested**
$36.14
💰 Most Recent Dividend Franked Percentage Estimate
100.00%
💰 Average Dividend Franked Percentage Estimate
100.00 %
💰 Dividend reinvestment
* Based on the most recent dividend
** Calculated by multiplying the most recent dividend yield by $1,000
Estimate your dividend
If you held
$
of CVC, your last dividend payment(s) would have been:
$ 286.86
on Fri Aug 18 2023
$ 285.71
on Mon Feb 20 2023
*Disclaimer: The information provided in this calculator is only a model to show you how long you need to invest for to achieve your goal, based on several factors, including past performance which is not an indicator of future performance. It is not a prediction and relies on assumptions, such as interest rates, that may vary and change the actual outcome. The results shown are only estimates and are not intended to be relied on when making a financial decision. Consider whether to get advice from a licensed financial adviser before making any financial decision.
Dividend History
1Y
5Y
10Y
Graph
Table
Year
Yearly Dividend Earnings Per Share
Franking Estimate
2024
$0.00
0.00%
2023
$0.09
100.00%
2022
$0.09
100.00%
2021
$0.08
100.00%
2020
$0.00
0.00%
2019
$0.15
100.00%
2018
$0.15
100.00%
2017
$0.13
100.00%
2016
$0.20
50.00%
2015
$0.15
33.33%
💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$2.06
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in CVC
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in CVC
N/A
CVC investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in CVC also invest in...
DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars.
🙌 Performance (5Yr p.a)
5.86%
📊 Share price
$8.21 AUD
🩺 HEALTH CARE
🌏 GLOBAL
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
13.23%
📊 Share price
$134.96 AUD
🌏 GLOBAL
🤖 TECHNOLOGY
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
ACDC.AX was created on 2018-08-30 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Battery ValueChain Index (the Index).
🙌 Performance (5Yr p.a)
12.66%
📊 Share price
$82.30 AUD
🤖 TECHNOLOGY
🏭 INDUSTRIALS
📈 HIGH PRICE GROWTH
🌏 GLOBAL
🛍️ CONSUMER
Argo Investments Ltd is a AU-based company operating in industry. The company is headquartered in Adelaide, South Australia. Argo Investments Limited is an Australia-based listed investment company (LIC). The firm manages a diversified portfolio of Australian shares with an internally managed business model. The principal activities of the Company include the investment of funds in Australian listed securities and short-term interest-bearing securities. Its investment objective is to maximize long-term shareholder returns through reliable fully franked dividend income and capital growth. Its investment portfolio comprises approximately 90 Australian companies from across a range of industries. Its portfolio includes investments in various sectors, such as materials, other financials, banks, healthcare, consumer staples, industrials, energy, consumer discretionary, property, utilities, listed investment companies, and others. Its subsidiary, Argo Service Company Pty Ltd, is engaged in providing investment management and administration operations for the Company.
🙌 Performance (5Yr p.a)
1.20%
📊 Share price
$8.99 AUD
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
4.00%
📊 Share price
$68.57 AUD
⛳️ DIVERSIFIED
🌏 GLOBAL
Want more shares? Try these...
Civmec Ltd is a AU-based company operating in Construction & Engineering industry. Civmec Limited, formerly Civmec Australia Limited, is an Australia-based multidisciplinary construction and engineering services provider to the energy, resources, infrastructure, marine and defense sectors. Its business activities include heavy engineering; shipbuilding; modularization; structural, mechanical, piping (SMP); electrical, instrumentation and control (EIC); precast concrete; site civil works; industrial insulation; maintenance; surface treatment; refractory; and access solutions. In the energy sector, it provides solutions for upstream and downstream energy projects. Its vertically integrated operating model supports the delivery of projects in the resource sector, allowing the Company to develop solutions for small or large greenfield and brownfield projects. The company delivers several infrastructure, marine and defense projects across Australia, which include Sydney Gateway Project and Kemerton Lithium Project. Its facilities are in Henderson, Port Hedland, and others.
🙌 Performance (5Yr p.a)
36.85%
📊 Share price
$1.26 AUD
📈 HIGH PRICE GROWTH
💰 HIGH DIVIDEND
👷♀️ CONSTRUCTION
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).
🙌 Performance (5Yr p.a)
-10.95%
📊 Share price
$13.04 AUD
🧬 BIOTECHNOLOGY
CurveBeam AI Ltd. engages in the research, design, and manufacture of cone beam computed tomography imaging systems. The company is headquartered in Hatfield, Pennsylvania. The company went IPO on 2023-08-23. The firm is engaged in providing point-of-care diagnostic cone beam CT imaging solutions with artificial intelligence (AI) and deep learning AI (DLAI). Its product categories include orthopedics and bone health. Its orthopedics products include HiRise, LineUP, pedCAT Premium, pedCAT, InReach, and CubeVue Software. Its bone health products include InReach HR-pQCT, and OSSView. HiRise is a bilateral, weight bearing CT imaging of the entire lower extremities including hips/pelvis, distal upper extremities. LineUP is a bilateral, weight bearing CT imaging of the distal lower extremities and distal upper extremities. InReach HR-pQCT is a high resolution peripheral quantitative CT (HR-pQCT) imaging system designed for the point-of-care. OssView Bone Fragility software analyzes HR-pQCT images to measure the bone microarchitecture.
📊 Share price
$0.10 AUD
🩺 HEALTH CARE